AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering therapies for inherited retinal diseases (IRDs), has announced the completion of enrollment in LUCE-1, their Phase 1/2 ...
A new generation of Indian founders is redefining ambition through substance, experience, and problem-solving. Spanning AI, ...
Our new 2,300-square-foot wellness space is my love letter to every caregiver. Now, there is finally a space designed for you ...
An editorial published in the New England Journal of Medicine 1 referred to the Photovoltaic Retina Implant Microarray (PRIMA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback